Sherbrooke Park Advisers LLC lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 36.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,017 shares of the company’s stock after selling 585 shares during the period. Sherbrooke Park Advisers LLC’s holdings in IDEXX Laboratories were worth $420,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of IDXX. Hurley Capital LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at $29,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at $31,000. Colonial Trust Co SC raised its holdings in shares of IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock valued at $35,000 after purchasing an additional 39 shares in the last quarter. Finally, Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at $38,000. Institutional investors and hedge funds own 87.84% of the company’s stock.
IDEXX Laboratories Stock Performance
Shares of IDXX opened at $518.10 on Friday. The company has a market capitalization of $41.67 billion, a PE ratio of 48.56, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $545.43. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The company’s fifty day moving average price is $431.28 and its 200 day moving average price is $431.28.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on the stock. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a report on Monday, April 14th. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a report on Monday, May 5th. Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, Piper Sandler raised their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $524.75.
Get Our Latest Stock Report on IDEXX Laboratories
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
- Five stocks we like better than IDEXX Laboratories
- How to invest in marijuana stocks in 7 steps
- Top 4 ETFs for China Exposure After Tariff Relief
- How to Invest in Small Cap Stocks
- Build a Complete Bond Portfolio With These 4 ETFs
- What is Forex and How Does it Work?
- MarketBeat Week in Review – 05/12 – 05/16
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.